{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:17:43Z","timestamp":1792282663284,"version":"4.4.0"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.phrs.2021.105864","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T23:53:06Z","timestamp":1630367586000},"page":"105864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics"],"prefix":"10.1016","volume":"173","author":[{"given":"Lokesh","family":"Thangamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6938-1495","authenticated-orcid":false,"given":"Balamuralikrishnan","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murugesh","family":"Easwaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeyakumar","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1597-6001","authenticated-orcid":false,"given":"Karthika","family":"Pushparaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Meyyazhagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmughavel","family":"Piramanayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105864_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105864_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-biophys-083012-130404","article-title":"Molecular mechanisms of RNA interference","volume":"42","author":"Wilson","year":"2013","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.phrs.2021.105864_bib3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/cvr\/cvr097","article-title":"Non-coding RNAs as regulators of gene expression and epigenetics","volume":"90","author":"Kaikkonen","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2021.105864_bib4","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.cell.2013.02.012","article-title":"Long noncoding RNAs: cellular address codes in development and disease","volume":"152","author":"Batista","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105864_bib5","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in caenorhabditiselegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105864_bib6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegansheterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105864_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/35053110","article-title":"Role for a bidentateribonuclease in the initiation step of RNA interference","volume":"409","author":"Bernstein","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105864_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt1051","article-title":"Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy","volume":"23","author":"Kim","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2021.105864_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0092-8674(00)80620-0","article-title":"RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals","volume":"101","author":"Zamore","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105864_bib10","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbrc.2006.02.049","article-title":"Chemical modification of siRNAs to improve serum stability without loss of efficacy","volume":"342","author":"Choung","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2021.105864_bib11","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1126\/science.1102514","article-title":"Crystal structure of argonaute and its implications for RISC slicer activity","volume":"305","author":"Song","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.105864_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2004.07.007","article-title":"Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs","volume":"15","author":"Meister","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2021.105864_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature02873","article-title":"Mechanisms of gene silencing by double-stranded RNA","volume":"431","author":"Meister","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105864_bib14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.addr.2009.04.018","article-title":"siRNA delivery systems for cancer treatment","volume":"61","author":"Oh","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.105864_bib15","first-page":"1087","article-title":"Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer","volume":"26","author":"Pal","year":"2005","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2021.105864_bib16","doi-asserted-by":"crossref","first-page":"6910","DOI":"10.1158\/0008-5472.CAN-05-0530","article-title":"Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery","volume":"65","author":"Landen","year":"2005","journal-title":"Cancer Res."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2021.105864_bib17","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1038\/modpathol.2008.11","article-title":"Targeted therapy of cancer: new roles for pathologists\u2014prostate cancer","volume":"21","author":"Rubin","year":"2008","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.phrs.2021.105864_bib18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.drudis.2008.05.007","article-title":"Chemically modified siRNA: tools and applications","volume":"13","author":"Watts","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2021.105864_bib19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.addr.2010.03.008","article-title":"Engineering rna for targeted sirna delivery and medical application","volume":"62","author":"Guo","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.105864_bib20","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/adhm.201600418","article-title":"Biomaterials in siRNA delivery: a comprehensive review","volume":"5","author":"Ho","year":"2016","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.phrs.2021.105864_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/nat.2016.0607","article-title":"Pharmacokinetic and pharmacodynamic Investigations of ION-353382, a model antisense oligonucleotide: using alpha-2-macroglobulin and murinoglobulin double-knockout mice","volume":"26","author":"Shemesh","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.phrs.2021.105864_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.7150\/thno.5743","article-title":"Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice","volume":"3","author":"Iversen","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2021.105864_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.105864_bib24","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2021.105864_bib25","article-title":"Unprecedented genomic diversity of RNA viruses in arthropods reveals the ancestry of negative-sense RNA viruses","volume":"2015","author":"Li","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.phrs.2021.105864_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41586-018-0012-7","article-title":"The evolutionary history of vertebrate RNA viruses","volume":"556","author":"Shi","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105864_bib27","unstructured":"ICTV, (n.d.). \u3008https:\/\/talk.ictvonline.org\/taxonomy\/\u3009. (Accessed 7 January 2021)."},{"key":"10.1016\/j.phrs.2021.105864_bib28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1743-422X-4-72","article-title":"Structural comparisons of the nucleoprotein from three negative strand RNA virus families","volume":"4","author":"Luo","year":"2007","journal-title":"Virol. J."},{"key":"10.1016\/j.phrs.2021.105864_bib29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1146\/annurev-biochem-060910-095130","article-title":"Structure unifies the viral universe","volume":"81","author":"Abrescia","year":"2012","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2021.105864_bib30","doi-asserted-by":"crossref","first-page":"96070","DOI":"10.1371\/journal.pone.0096070","article-title":"Evolution of tertiary structure of viral RNA dependent polymerases","volume":"9","author":"\u010cern\u00fd","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2021.105864_bib31","doi-asserted-by":"crossref","first-page":"8378","DOI":"10.1073\/pnas.1703834114","article-title":"Virus found in a boreal lake links ssDNA and dsDNA viruses","volume":"114","author":"Laanto","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105864_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01402-19","article-title":"New phylogenetic grouping of positive-sense RNA viruses is concordant with replication complex morphology","volume":"10","author":"Ahola","year":"2019","journal-title":"MBio"},{"key":"10.1016\/j.phrs.2021.105864_bib33","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/tpbi.2002.1591","article-title":"Evolution of viral structure","volume":"61","author":"Bamford","year":"2002","journal-title":"Theor. Popul. Biol."},{"key":"10.1016\/j.phrs.2021.105864_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-94-007-4899-6_5","article-title":"Virus universe: can it be constructed from a limited number of viral architectures","author":"Oksanen","year":"2012","journal-title":"Virus Essent. Agents Life"},{"key":"10.1016\/j.phrs.2021.105864_bib35","article-title":"The Spanish Influenza Pandemic: a lesson from history 100 years after 1918","volume":"60","author":"Martini","year":"2019","journal-title":"J. Prev. Med. Hyg."},{"key":"10.1016\/j.phrs.2021.105864_bib36","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3399\/bjgp09X453882","article-title":"History lessons: the Asian Flu pandemic","volume":"59","author":"Jackson","year":"2009","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.phrs.2021.105864_bib37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3201\/eid0502.990202","article-title":"The next influenza pandemic: lessons from Hong Kong, 1997","volume":"5","author":"Snacken","year":"1999","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.phrs.2021.105864_bib38","doi-asserted-by":"crossref","DOI":"10.2807\/ese.13.49.19056-en","article-title":"The Russian influenza in Sweden in 1889-90: an example of Geographic Information System analysis","volume":"13","author":"Skog","year":"2008","journal-title":"Euro Surveill."},{"key":"10.1016\/j.phrs.2021.105864_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens5040066","article-title":"Reviewing the history of pandemic influenza: Understanding patterns of emergence and transmission","volume":"5","author":"Saunders-Hastings","year":"2016","journal-title":"Pathogens"},{"key":"10.1016\/j.phrs.2021.105864_bib40","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/CMR.00023-07","article-title":"Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection","volume":"20","author":"Cheng","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.phrs.2021.105864_bib41","article-title":"Facing the HIV\/AIDS pandemic","volume":"57","author":"Lamptey","year":"2002","journal-title":"Popul. Bull."},{"key":"10.1016\/j.phrs.2021.105864_bib42","article-title":"Management of swine flu (H1N1 Flu) outbreak and its treatment guidelines","volume":"2","author":"Mukherjee","year":"2015","journal-title":"Commun. Acquir. Infect."},{"key":"10.1016\/j.phrs.2021.105864_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2221-1691(15)30365-8","article-title":"Ebola virus disease: past, present and future","volume":"5","author":"Rajak","year":"2015","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"10.1016\/j.phrs.2021.105864_bib44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41541-020-0170-0","article-title":"The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines","volume":"5","author":"Shang","year":"2020","journal-title":"Npj Vaccin."},{"key":"10.1016\/j.phrs.2021.105864_bib45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12879-016-2137-3","article-title":"Outbreak of Middle East respiratory syndrome coronavirus in Saudi Arabia: a retrospective study","volume":"17","author":"Aleanizy","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.phrs.2021.105864_bib46","unstructured":"Coronavirus Disease (COVID-19) Situation Reports, (n.d.). \u3008https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports\u3009 (Accessed 7 January 2021)."},{"key":"10.1016\/j.phrs.2021.105864_bib47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2180-1-34","article-title":"Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses","volume":"1","author":"Bitko","year":"2001","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.phrs.2021.105864_bib48","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1073\/pnas.252783999","article-title":"Interference of hepatitis C virus RNA replication by short interfering RNAs","volume":"100","author":"Kapadia","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105864_bib49","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","article-title":"Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study","volume":"375","author":"Geisbert","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2021.105864_bib50","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3851\/IMP3153","article-title":"Topical treatment of herpes simplex virus infection with enzymatically created siRNA swarm","volume":"22","author":"Paavilainen","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.phrs.2021.105864_bib51","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00705-018-3757-2","article-title":"Inhibition of dengue virus infection by small interfering RNAs that target highly conserved sequences in the NS4B or NS5 coding regions","volume":"163","author":"Villegas","year":"2018","journal-title":"Arch. Virol."},{"key":"10.1016\/j.phrs.2021.105864_bib52","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.1073\/pnas.0402486101","article-title":"Inhibition of influenza virus production in virus-infected mice by RNA interference","volume":"101","author":"Ge","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105864_bib53","doi-asserted-by":"crossref","first-page":"8682","DOI":"10.1073\/pnas.0402630101","article-title":"Protection against lethal influenza virus challenge by RNA interference in vivo","volume":"101","author":"Tompkins","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105864_bib54","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.molmed.2004.10.004","article-title":"The promise of siRNAs for the treatment of influenza","volume":"10","author":"Bennink","year":"2004","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.phrs.2021.105864_bib55","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1128\/JVI.79.4.2151-2159.2005","article-title":"Inhibition of Coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand","volume":"79","author":"Yuan","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.phrs.2021.105864_bib56","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1128\/JVI.79.13.8620-8624.2005","article-title":"A small interfering RNA targeting coxsackievirus B3 protects permissive HeLa cells from viral challenge","volume":"79","author":"Ahn","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.phrs.2021.105864_bib57","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1128\/JVI.78.14.7523-7527.2004","article-title":"Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells","volume":"78","author":"Wang","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.phrs.2021.105864_bib58","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.virol.2004.03.031","article-title":"Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase","volume":"324","author":"Lu","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.phrs.2021.105864_bib59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0014-5793(04)00087-0","article-title":"Silencing SARS-CoV spike protein expression in cultured cells by RNA interference","volume":"560","author":"Zhang","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2021.105864_bib60","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm1280","article-title":"Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque","volume":"11","author":"Li","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2021.105864_bib61","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1128\/JVI.78.13.6900-6907.2004","article-title":"RNA interference targeting VP1 inhibits foot-and-mouth disease virus replication in BHK-21 cells and suckling mice","volume":"78","author":"Chen","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.phrs.2021.105864_bib62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.virol.2005.01.051","article-title":"Cross-inhibition to heterologous foot-and-mouth disease virus infection induced by RNA interference targeting the conserved regions of viral genome","volume":"336","author":"Liu","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.phrs.2021.105864_bib63","first-page":"401","article-title":"Selective silencing of viral gene E6 and E7 expression in HPV-positive human cervical carcinoma cells using small interfering RNAs","volume":"292","author":"Jiang","year":"2005","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.phrs.2021.105864_bib64","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/sj.emboj.7600651","article-title":"HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs","volume":"24","author":"Longworth","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2021.105864_bib65","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1525-0016(03)00244-2","article-title":"Small interfering RNA inhibits hepatitis B virus replication in mice","volume":"8","author":"Giladi","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2021.105864_bib66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-5793(03)00400-9","article-title":"Short interfering RNA-directed inhibition of hepatitis B virus replication","volume":"543","author":"Hamasaki","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2021.105864_bib67","first-page":"842","article-title":"Inhibition of HBV replication by siRNA in a stable HBV-producing cell line","volume":"38","author":"Konishi","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2021.105864_bib68","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/jhep.2003.50146","article-title":"Inhibition of hepatitis B virus expression and replication by RNA interference","volume":"37","author":"Shlomai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2021.105864_bib69","doi-asserted-by":"crossref","first-page":"14392","DOI":"10.1128\/JVI.79.22.14392-14403.2005","article-title":"Genomic analysis of Anti-Hepatitis B Virus (HBV) activity by small interfering RNA and Lamivudine in stable HBV-producing cells","volume":"79","author":"Guo","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.phrs.2021.105864_bib70","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ymthe.2005.10.013","article-title":"Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs","volume":"13","author":"Carmona","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2021.105864_bib71","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nbt824","article-title":"Inhibition of hepatitis B virus in mice by RNA interference","volume":"21","author":"McCaffrey","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2021.105864_bib72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrd.2017.251","article-title":"Post-exposure treatments for Ebola and Marburg virus infections","volume":"17","author":"Cross","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105864_bib73","doi-asserted-by":"crossref","first-page":"1001997","DOI":"10.1371\/journal.pmed.1001997","article-title":"Experimental treatment of Ebola Virus Disease with TKM-130803: a single-arm phase 2 clinical trial","volume":"13","author":"Dunning","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.phrs.2021.105864_bib74","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: a progress report on siRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.phrs.2021.105864_bib75","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd4685","article-title":"Clinical experiences with systemically administered siRNA-based therapeutics in cancer","volume":"14","author":"Zuckerman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105864_bib76","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.7150\/thno.15246","article-title":"Pharmacokinetic behaviors of intravenously administered siRNA in glandular tissues","volume":"6","author":"Huang","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2021.105864_bib77","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/mt.2010.266","article-title":"Elimination pathways of systemically delivered siRNA","volume":"19","author":"Huang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2021.105864_bib78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105864_bib79","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2085","article-title":"Illuminating the silence: Understanding the structure and function of small RNAs","volume":"8","author":"Rana","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2021.105864_bib80","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2021.105864_bib81","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ab.2006.11.001","article-title":"Analysis of 2\u2032-O-methylated nucleosides and pseudouridines in ribosomal RNAs using DNAzymes","volume":"361","author":"Buchhaupt","year":"2007","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.phrs.2021.105864_bib82","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bph.12330","article-title":"Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy","volume":"170","author":"Guzman-Aranguez","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105864_bib83","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N -acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2021.105864_bib84","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.phrs.2021.105864_bib85","unstructured":"Home - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/\u3009 (Accessed 7 January 2021)."},{"key":"10.1016\/j.phrs.2021.105864_bib86","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1021\/acs.nanolett.6b02915","article-title":"PH-Sensitive nanomicelles for high-efficiency siRNA delivery in vitro and in vivo: an insight into the design of polycations with robust cytosolic release","volume":"16","author":"Zhou","year":"2016","journal-title":"Nano Lett."},{"key":"10.1016\/j.phrs.2021.105864_bib87","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cld.2010.09.002","article-title":"Infectious diseases and the liver","volume":"15","author":"Talwani","year":"2011","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.phrs.2021.105864_bib88","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.path.2018.02.008","article-title":"Granulomas in the Liver, with a focus on infectious causes","volume":"11","author":"Choi","year":"2018","journal-title":"Surg. Pathol. Clin."},{"key":"10.1016\/j.phrs.2021.105864_bib89","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2893.2002.00381.x","article-title":"Regulatory elements of hepatitis B virus transcription","volume":"9","author":"Moolla","year":"2002","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.phrs.2021.105864_bib90","doi-asserted-by":"crossref","first-page":"163","DOI":"10.20517\/2394-5079.2016.05","article-title":"Hepatitis B virus molecular biology and pathogenesis","volume":"2","author":"Lamontagne","year":"2016","journal-title":"Hepatoma Res."},{"key":"10.1016\/j.phrs.2021.105864_bib91","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2021.105864_bib92","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.30325","article-title":"Serum Hepatitis B Virus RNA: a new potential biomarker for chronic Hepatitis B virus infection","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2021.105864_bib93","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-981-13-9151-4_6","article-title":"Present and Future Therapies for Chronic Hepatitis B","author":"Tao","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.phrs.2021.105864_bib94","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cbpa.2019.02.009","article-title":"Recent advances in the development of HBV capsid assembly modulators","volume":"50","author":"Nijampatnam","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.phrs.2021.105864_bib95","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2021.105864_bib96","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan MicroRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105864_bib97","article-title":"Regulation of microRNA biogenesis and its crosstalk with other cellular pathways","volume":"20","author":"Treiber","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2021.105864_bib98","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.phrs.2021.105864_bib99","doi-asserted-by":"crossref","first-page":"12982","DOI":"10.1073\/pnas.0703778104","article-title":"Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes","volume":"104","author":"Rozema","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105864_bib100","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cpdd.318","article-title":"Safety, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the treatment of chronic Hepatitis B Virus Infection, in healthy volunteers","volume":"6","author":"Schluep","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.phrs.2021.105864_bib101","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","article-title":"Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor","volume":"531","author":"Decorsi\u00e8re","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105864_bib102","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2796.2009.02189.x","article-title":"Lipid-based nanotherapeutics for siRNA delivery","volume":"267","author":"Schroeder","year":"2010","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2021.105864_bib103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA interference therapy with ARC-520 results in prolonged Hepatitis B surface antigen response in patients with chronic Hepatitis B infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2021.105864_bib104","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2021.105864_bib105","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/nar\/gky037","article-title":"Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo","volume":"46","author":"Hassler","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2021.105864_bib106","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1111\/liv.13656","article-title":"Towards HBV curative therapies","volume":"38","author":"Schinazi","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.phrs.2021.105864_bib107","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"Rnai-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis b virus DNA is a source of hbsag","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2021.105864_bib108","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.omtn.2018.02.005","article-title":"Liver-targeted anti-HBV single-stranded oligonucleotides with locked nucleic acid potently reduce hbv gene expression","volume":"11","author":"Javanbakht","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.phrs.2021.105864_bib109","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2353\/ajpath.2006.051296","article-title":"Systemic viral infections and collateral damage in the liver","volume":"168","author":"Adams","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2021.105864_bib110","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnz009","article-title":"Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management","volume":"41","author":"Marjot","year":"2020","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.phrs.2021.105864_bib111","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2021.105864_bib112","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbic.201500023","article-title":"Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo","volume":"16","author":"Rajeev","year":"2015","journal-title":"ChemBioChem"},{"key":"10.1016\/j.phrs.2021.105864_bib113","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1021\/bc00036a006","article-title":"Cell-type specific and ligand specific enhancement of cellular uptake of oligodeoxynucleosi de methylphosphonates covalently linked with a neoglycopeptide, YEE(ah-GalNAc)3","volume":"6","author":"Hangeland","year":"1995","journal-title":"Bioconjug. Chem."},{"issue":"Pt. 3","key":"10.1016\/j.phrs.2021.105864_bib114","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1042\/bj3400783","article-title":"Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo","volume":"340","author":"Biessen","year":"1999","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2021.105864_bib115","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/cb501028c","article-title":"siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes","volume":"10","author":"Matsuda","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2021.105864_bib116","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"NAR breakthrough article targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T01:48:23Z","timestamp":1734400103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821004485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":116,"alternative-id":["S1043661821004485"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105864","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105864"}}